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Mitochondria are recognized as critical sites of localized injury in a number of chronic pathologies
which has led to the development of organelle directed therapeutics. One of the approaches employed
to target molecules to the mitochondrion is to conjugate a delocalized cation such as triphenylpho-
sphonium (TPPþ) to various redox active compounds. Mitochondrially targeted antioxidants have also
been used in numerous cell culture based studies as probes of the contribution of the mitochondrial
generation of reactive oxygen species on cell signaling events. However, concentrations used in vitro are
typically 10–100 times greater than those generated from oral dosing in a wide range of animal models
and in humans. In the present study, we determined the effects of mitochondrial targeted antioxidants,
MitoQ, MitoTempol, and MitoE on cellular bioenergetics of mesangial cells in culture and compared
these to TPPþ conjugated compounds which lack the antioxidant functional group. We found that all
TPPþ compounds inhibited oxidative phosphorylation to different extents independent of the
antioxidant functional groups. These ﬁndings show that the TPPþ moiety can disrupt mitochondrial
function at concentrations frequently observed in cell culture and this behavior is dependent on the
linker group and independent of antioxidant properties. Moreover, the TPPþ moiety alone is unlikely to
achieve the concentrations needed to contribute to the protective mechanisms of the mitochondrially
targeted compounds that have been reported in vivo.
& 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license. Introduction
It is clear that the pathological mechanisms of several diseases
are associated with increased mitochondrial oxidative stress and
consequently bioenergetic dysfunction. This is expected since
mitochondria are both producers and targets of reactive oxygen
and nitrogen species (ROS/RNS). In many cases, mitochondrial
dysfunction occurs due to oxidative modiﬁcation of the respira-
tory chain complexes which then ampliﬁes and promotes furtherer B.V.
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Open access under CC BY-NC-Noxidative damage. The precise mechanisms are still under active
investigation but it appears that the mitochondrion is particularly
vulnerable to reactive lipid species which are formed by lipid
peroxidation [1]. Reactive lipid species appear to target the
mitochondria by inducing the formation of superoxide and
hydrogen peroxide which can ultimately result in bioenergetic
dysfunction and mitophagy [2–4]. In particular, mitophagy is
essential for maintaining mitochondrial quality control and cell
survival and is largely dependent on mtDNA integrity, oxidative
phosphorylation, and autophagy [5]. These pathways can be
modiﬁed by ROS/RNS and are therefore potentially amenable to
treatment with mitochondrially targeted antioxidants. Several
strategies have been developed to target small molecule antiox-
idants to the mitochondria to assess their ability to suppress
oxidative stress in various disease models [6,7]. For example,
Mitoquinone (MitoQ) has been tested successfully in human
diseases such as Hepatitis C induced liver disease and skin photo
damage as well as a number of experimental animal models
including ischemia-reperfusion, neurodegenerative diseases, dia-
betes, and alcohol-induced hepatosteatosis [8–14]. These ﬁndings
support the concept that mitochondrially targeted antioxidants
may be clinically beneﬁcial by preventing aberrant redox signaling
and oxidative stress in the mitochondrion.D license. 
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mitochondrion and one of the most versatile is to conjugate a
pharmacophore to lipophilic cations such as triphenylphospho-
nium (TPPþ) [6]. This delocalized cation is hydrophobic and can
freely pass through the phospholipid bilayers of the plasma
membrane and other organelles, without the requirement
for a speciﬁc uptake mechanism. This is achieved because the
cells’ negative plasma membrane potential (-30mV to -60mV)
drives the movement of TPPþ from the extracellular space
into the cytoplasmic compartment up to 10-fold. TPPþ can
further accumulate within the mitochondria up to several
hundred fold due to the higher mitochondrial membrane
potential (140 to 180 mV) [15,16]. It has been determined
that there is an approximately tenfold accumulation of TPPþ
within the mitochondria for every 60 mV increase in mitochon-
drial membrane potential [17]. Because the extent of uptake of a
TPPþ conjugated compound depends on the plasma and mito-
chondrial membrane potential, the volume of the incubation, the
cell volume, and the number of mitochondria within a given cell,
the quantity of the compound found within mitochondria can
vary substantially between different cell types [18]. Further, the
therapeutic molecules employing the TPPþ moiety use varying
carbon chain linkers to attach functional groups, it is important to
understand how the cell responds to changes in the physical
properties of TPPþ mitochondria-directed compounds. Once
inside the mitochondrion, TPPþ molecules are primarily posi-
tioned on the mitochondrial matrix facing surface of the phos-
pholipid bilayer, with the linker and functional group positioned
within the inner membrane [19,20]. The extent of anchoring of
the TPPþ molecules to the inner mitochondrial membrane is
dependent upon the hydrophobicity, the length of the linker unit,
and the functional group [17]. The membrane anchoring of the
TPPþ molecules accumulated within mitochondria can elicit
beneﬁcial effects such as scavenging reactive radicals, preventing
membrane lipid peroxidation, controlling mitochondrial redox
signaling and/or modify any pharmacological effects of the
TPPþ group.
It has been shown that the physical properties of the TPPþ
conjugated compounds and the linker chain can also determine
the extent of accumulation of the molecule within the mitochon-
dria. For example, triphenylmethylphosphonium (TPMP), a one
carbon methyl attached to TPPþ , has relatively low hydrophobi-
city and slow rates of accumulation into mitochondria within
cells compared to TPPþ molecules which are more hydrophobic
due to longer carbon linkers [17,21]. The efﬁcacy of the targeted
antioxidant group also varies depending on its linker chain length
owing to the differences in their physical properties and access to
the active sites of activating and recycling enzymes such as
complex II. The TPPþ moiety can also in principle have pharma-
cological or inhibitory properties due to its interactions with
mitochondria which can potentially be modiﬁed by both the
linker group and the functional pharmacophores possessing
antioxidant properties [19].
Properties of TPPþ conjugated compounds have been exten-
sively studied in cell culture systems. For example, high concen-
trations of TPPþ were shown to contribute to intra-mitochondrial
calcium regulation in HELA cells stimulated with inositol 1,4,5-
trisphosphate, where both MitoQ and TPPþ treatment signiﬁcantly
increased mitochondrial matrix calcium concentrations [22]. It was
also shown that calcium efﬂux from the mitochondria was delayed
after exposure to these targeted compounds [22]. This study
indicated that TPPþ itself inhibits the Naþ (or Hþ)/Ca2þ exchanger
and thus increases intra-mitochondrial calcium levels. The degree
of inhibition for the mitochondrial Naþ(or Hþ)/Ca2þ exchanger
was greater with TPPþ compared to MitoQ [22]. Mitochondrial
targeted antioxidants have also been used as probes to examinethe contribution of mitochondrial ROS to cell signaling events. In
human breast cancer cells, MitoQ was shown to inhibit cell
proliferation through autophagy and apoptotic cell death mechan-
isms [23]. Speciﬁcally, MitoQ caused phosphorylation of check-
point kinases and disassociation of Keap1 from Nrf2, leading to
increased Nrf2 transcription activity [23]. In rat cardiac myoblasts,
both MitoQ and MitoTempol were determined to inhibit muscle
differentiation mediated by hydrogen peroxide signaling without
altering ATP levels [24]. Most recently, it has been determined that
MitoQ uncouples mitochondria when added to bovine aortic
endothelial cells at concentrations of 150 nM and higher in a dose
dependent fashion and simultaneously induces glycolysis [25]. In
the studies mentioned above, the concentrations of all of the
mitochondrial targeted antioxidants were higher than those that
can be achieved pharmacologically and associated with protective
effects in vivo [26].
Thus, it is increasingly clear that modiﬁcations to the linker,
the mitochondrial targeting group, and the functional group are
important in determining the biological properties of mitochond-
rially targeted compounds. Therefore, it is important to further
assess these properties by carrying out a systematic investigation
of the effects of TPPþ conjugated compounds over a concentra-
tion range which encompasses the low nM levels which are found
pharmacologically. Here, we investigate the cellular bioenergetic
response, speciﬁcally the oxygen consumption (OCR) and pH
(ECAR) rates of MES-13 cells to selected pharmacophores attached
to TPPþ using a Seahorse Biosciences XF-24 ﬂux analyzer. Although
effects on cellular bioenergetics are consistently observed with TPPþ
conjugated compounds these typically occur at concentrations at
least one order of magnitude or greater than the levels associated
with beneﬁcial effects in disease model and are unlikely to con-
tribute to the mechanism of action in vivo. They also suggest that the
use of mitochondrially targeted antioxidants in cell culture systems
to test for the role of mitochondrially reactive oxygen species should
be controlled for the non-speciﬁc effects of the TPPþ and linker
groups.Materials and methods
Reagents
Oligomycin, FCCP (carbonyl cyanide 4-(triﬂuoromethoxy) phe-
nylhydrazone), Antimycin A, TPMP (triphenylmethylphospho-
nium), BTPP (butyl triphenylphosphonium), and DTPP (decyl
triphenylphosphonium) were all obtained from Sigma-Aldrich
(St. Louis, MO, USA). MitoQ (Mitoquinone), MitoTempol, and
MitoE were provided by Drs. Michael P. Murphy and Balaraman
Kalyanaraman.
Cell culture
Mouse kidney mesangial cells (MES-13) were purchased from
ATCC (Manassas, VA) and maintained in a humidiﬁed incubator
gassed with 5% CO2 at 37 1C. Cells were grown in Dulbecco’s
Modiﬁed Eagles Medium (DMEM, Cellgro) supplemented with
D-Glucose (5.5 mM, Sigma-Aldrich), HAM’s F-12 1X (Cellgro),
L-Glutamine (4mM, Invitrogen), penicillin and streptomycin
(100U/mL and 100 ng/mL, respectively, Invitrogen) and 2.5% fetal
bovine serum (Atlanta Biologicals).
TPP derivatives
TPMP, BTPP, and DTPP compounds contain side chains of varying
lengths (methyl group, butyl group, and decyl group respectively)
without antioxidant groups (Fig. 1A–C). MitoQ, MitoTempol, and
ButylTPPTPMP
DecylTPP
MitoQ
MitoTempol
MitoE
Fig. 1. Chemical structures of TPPþ derivatives. (A–C) TPMP, BTPP, and DTPP are
control TPPþ derivatives used to distinguish the effects of the antioxidant
functional group versus the targeting moiety and the alkyl linker chain. (D–F)
MitoQ, MitoTempol, and MitoE are TPPþ derivatives comprised of functional
antioxidant groups.
Fig. 2. Schematic of bioenergetic proﬁle used to evaluate the acute effects of
mitochondrial targeted compounds on mitochondrial function.
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(Fig. 1D–F). MitoQ was synthesized by the covalent addition of
quinol to a lipophilic TPPþ moiety through an aliphatic carbon chain
[27]. MitoTempol is comprised of the piperidine nitroxide TEMPOL
conjugated to an aliphatic carbon chain terminating with a TPPþ
moiety [28]. MitoE was generated by conjugating Vitamin E (a-
tocopherol) to a lipophilic TPPþ cation [29].
Measurement of mitochondrial function using the Seahorse
XF-24 extracellular ﬂux analyzer
To test the effects of TPP derivatives on cellular bioenergetics
in MES-13 cells, the Seahorse XF-24 analyzer from Seahorse
Biosciences (North Billerica, MA) was utilized. MES-13 cells were
seeded 30,000 cells per well in Seahorse XF-24 specialized cell
culture plates. Approximately 24 h later, media was replaced with
unbuffered DMEM for 1 h at 37 1C prior to assessing basal oxygen
consumption rate (OCR) or extracellular acidiﬁcation rate (ECAR)simultaneously in the Seahorse XF-24 extracellular ﬂux analyzer.
Thirty min later, all of the TPPþ derivatives were injected
individually to MES-13 cells (0, 0.01, 0.1, or 1 mM). The effect of
the TPPþ derivatives on bioenergetics was measured for two
hours followed by evaluation of the metabolic proﬁle using the
mitochondrial function assay [30] (Fig. 2). Basal OCR and ECAR
was measured over time followed by observing the effects of the
mitochondrial inhibitors, oligomycin (1 mg/mL), FCCP (2 mM), and
antimycin A (10 mM). The cellular bioenergetic parameters deter-
mined were ATP linked respiration, proton leak, maximal, and
reserve capacity. ATP linked respiration was derived from the
difference between OCR at baseline and respiration following
oligomycin addition. The difference in OCR between antimycin A
and oligomycin represented the amount of oxygen consumed that
is due to proton leak. Maximal OCR was determined by subtract-
ing the OCR after antimycin A addition from the OCR induced by
FCCP. Lastly, the reserve capacity was calculated by the difference
between maximal (FCCP) and basal respiration. All data is
expressed as a percentage of the basal OCR or ECAR before TPPþ
derivative injection to allow comparison between the different
compounds.
Statistical analysis
All results are expressed as means7SEM (n¼3–5 per group).
An unpaired Student’s t test was used to compare the control and
treated groups. ANOVA and the Newman–Keuls test were used to
compare the mean values for multiple group comparisons.
All values were considered signiﬁcant at Po0.05.Results and discussion
The effects of lengthening the alkyl chain of TPPþ derivatives on
cellular bioenergetics
TPMP is the methylated form of TPPþ and is the simplest
derivative used in this study (Fig. 1A). It is a commonly used
control for more complex derivatives containing an antioxidant or
other functional groups to rule out a contribution of the TPPþ
moiety to an observed biological effect. Fig. 3A shows the effects
of TPMP (0.1 mM and 1 mM) on cellular bioenergetics. Cells were
allowed to establish a stable baseline and then TPMP was injected
into the cell media as shown. The lower concentration of TPMP
(0.1 mM) had no signiﬁcant affect on basal OCR whereas 1 mM
TPMP progressively decreased OCR over a 2 h period. At this
point a mitochondrial function assay was performed using
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Fig. 3. Acute effects of TPMP, BTPP, and DTPP on oxygen consumption rate (OCR).
MES-13 cells were seeded in a Seahorse XF-24 plate at 30,000 cells per well for
24 h. Cellular media was replaced with low-buffered DMEM media prior to the
assay and allowed to equilibrate for 1 h at 37 1C. Basal OCR measurements were
made followed by injection of (A) TPMP (0.1 mM or 1 mM), (B) BTPP (1 mM), or
(C) DTPP (1 mM). After assessing the acute effects of the TPPþ controls, oligomycin
(1 mg/mL), FCCP (2 mM), and AA (10 mM) were injected. Data is expressed as a
percent relative to the basal OCR rate before TPMP, BTPP, or DTPP injection. All
data shown are mean7SEM, n¼3–5 group.
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Fig. 4. Acute effects of TPMP, BTPP, and DTPP on extracellular acidiﬁcation rate
(ECAR). MES-13 cells were seeded in a Seahorse XF-24 plate at 30,000 cells per
well for 24 h. The following day basal ECAR was determined prior to injecting
(A) TPMP (0.1 mM or 1 mM), (B) BTPP (1 mM), or (C) DTPP (1 mM) into the cellular
medium. Subsequently, oligomycin (1 mg/mL), FCCP (2 mM), and AA (10 mM) was
injected to further evaluate glycolysis. Data is expressed as a percent relative to
the basal ECAR rate before TPMP, BTPP, or DTPP injection. All data shown are
mean7SEM, n¼3–5 group.
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caused a substantial decrease in OCR in control cells which was
signiﬁcantly suppressed by TPMP. To determine the maximal
respiratory capacity, FCCP was injected into the media and caused
an increase in OCR measured relative to the point prior to the
addition of oligomycin. Interestingly, the stimulation of respira-
tion with FCCP after oligomycin was substantially greater in the
presence of 1 mM TPMP. Lastly, injection of antimycin A signiﬁ-
cantly inhibited respiration in all groups with a signiﬁcantly
greater effect on the TPMP (1 mM) treated cells. The ECAR was
measured as an index of glycolysis under the same conditions as
shown in Fig. 4. Immediately upon addition of TPMP, ECAR
increased such that the maximal level was reached approximately
1 h after its addition (Fig. 4A). In the control cells, the maximum
ECAR was elicited upon the addition of FCCP and this was not
further increased in the TPMP (1 mM) treated cells.
We next examined the effects of lengthening the alkyl chain
on cellular bioenergetics using two additional compounds, BTPP
and DTPP using the protocol established for TPMP (Fig. 3B, C). In
contrast to TPMP, cells exposed to 1 mM BTPP showed no changes
in any of the bioenergetic parameters measured compared to
control cells (Fig. 3B). DTPP (1 mM) caused a transient decrease inbasal OCR which reverted back to control levels within 20 min
(Fig. 3C). However, addition of oligomycin did not elicit the
anticipated decrease in OCR and further addition of FCCP resulted
in an inhibition of respiration rather than a stimulatory response.
Antimycin A inhibited OCR to the same extent as controls
indicating that these responses are mitochondrial in origin.
As shown in Fig. 4B, BTPP had no effect on the cellular basal
glycolytic rate. However, DTPP induced a rapid increase in basal
ECAR and this was not further stimulated upon addition of
oligomycin or FCCP (Fig. 4C).
It is clear from these data that the TPPþ group has a functional
impact on cellular bioenergetics which is highly sensitive to the
alkyl linker groups which have previously been assumed to be
largely inert. Much of this effect may be due to the increased
extent of uptake of the TPP molecules when conjugated to a more
hydrophobic carbon chain. The effects of TPMP are to inhibit basal
respiration but have a minimal effect on the maximal respiration.
Since FCCP will result in depolarization of the mitochondrial inner
membrane and loss of TPMP from the mitochondrial matrix, it
C. Reily et al. / Redox Biology 1 (2013) 86–9390suggests the effects of TPMP on oxidative phosphorylation are
reversible. The rapid increase in ECAR by the cells exposed to
TPMP indicates activation of glycolysis to compensate for loss of
mitochondrial ATP production. In contrast, DTPP behaves quite
differently in that oligomycin sensitivity is now completely
diminished which is consistent with a rapid cycling of DTPP
between the mitochondrial matrix and cytosol thereby decreasing
the control of respiration by the proton electrochemical potential
gradient, effectively uncoupling mitochondria.
The effects of adding an antioxidant functional group to alkyl TPPþ
chain on cellular bioenergetics
To assess the impact of coupling a functional group to the alkyl
TPPþ moiety, we investigated the effects of MitoQ, MitoTempol,
and MitoE (Fig. 1D–F). The bioenergetic response of cells to 1 mM
MitoQ is shown in Fig. 5A. After the cells established a stable
baseline, MitoQ was injected into the cellular media and caused a
steady decline in oxygen consumption over 2 h. Surprisingly,
oligomycin did not elicit a pronounced decrease in cellular150 F
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Fig. 5. Acute effects of MitoQ, MitoTempol, and MitoE on oxygen consumption
rate (OCR). MES-13 cells were seeded in a Seahorse XF-24 plate at 30,000 cells per
well for 24 h. Cellular media was replaced with low-buffered DMEM media prior
to the assay and allowed to equilibrate for 1 h at 37 1C. Basal OCR measurements
were made for approximately 30 min followed by injection of (A) MitoQ (1 mM),
(B) MitoTempol (1 mM), or (C) MitoE (1 mM). Two hours later, the effects of
oligomycin (1 mg/mL), FCCP (2 mM), and AA (10 mM) treatment were determined.
Data is expressed as a percent relative to the basal OCR rate before MitoQ,
MitoTempol, or MitoE injection. All data shown are mean7SEM, n¼3–5 group.respiration as expected nor did FCCP stimulate respiration. How-
ever, antimycin A inhibited respiration to levels similar to control
cells. The effects of MitoQ on glycolysis (Fig. 6A) were determined
based on the parameters measured in Fig. 5A. MitoQ caused an
initial transient increase in ECAR that returned back to basal
levels within 2 h (Fig. 6A). Glycolysis increased minimally follow-
ing oligomycin injection and was not further stimulated with
FCCP or antimycin A treatment (Fig. 6A) suggesting that MitoQ is
disrupting the ability of the respiratory chain to transfer electrons
to oxygen.
The effects of MitoTempol (1 mM) on cellular oxygen con-
sumption are shown in Fig. 5B. Following basal OCR readings,
MitoTempol was added to the cells and caused a progressive
decline in mitochondrial respiration, which was later shown to be
exacerbated with oligomycin and FCCP treatment. Mitochondrial
respiration was further inhibited to control levels with antimycin
A injection. Interestingly, the respiratory response to the mito-
chondrial assay in MitoTempol treated cells was analogous to the
response mediated by DTPP (Fig. 3B). These ﬁndings suggest that
MitoTempol may be decreasing respiration in a similar manner as
DTPP. As shown in Fig. 6B, MitoTempol caused a steady increase
in ECAR for 20 min before continuously declining over a 2 h
period.AA300 F
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injection. Reserve capacity is the difference between basal and Maximal OCR. Data is expressed as a percent relative to the basal OCR rate before compound injection. All
data shown are mean7SEM, n¼3–5 group. npo0.05 vs. untreated controls, statistical comparison performed using ANOVA and Newman–Keuls.
Table 1
Bioenergetic proﬁles of non-mitochondrially targeted antioxidants. MES-13 cells
were seeded in a Seahorse XF-24 plate at 30,000 cells per well for 24 h. Cellular
media was replaced with low-buffered DMEM media prior to the assay and
allowed to equilibrate for 1 h at 37 1C. Basal OCR measurements were made for
approximately 30 min followed by injection of Coenzyme Q10 (1 mM), Tempol
(1 mM), or Vitamin E (1 mM). Two hours later, the effects of oligomycin (1 mg/mL),
FCCP (2 mM), and AA (10 mM) treatment were determined. Basal OCR is calculated
as the difference in OCR before compound injection and after two hours of
exposure. ATP linked is the difference in OCR before and after Oligomycin. Proton
Leak is the difference in OCR after oligomycin injection and antimycin A. Maximal
is the OCR following FCCP injection. Data is expressed as a percent relative to the
basal OCR rate before compound injection. All data shown are mean7SEM, n¼3–
5 group. *, po0.05 vs. untreated controls, statistical comparison performed using
ANOVA and Newman–Keuls.
Bioenergetic proﬁles of Non-mitochondrially targeted antioxidants
Basal OCR (%)
Coenzyme Q10 1 mM 9971.2
Tempol 1 mM 8971.7
Vitamin E 1 mM 10372.4
ATP linked OCR (%)
Coenzyme Q10 1 mM 7272.5
Tempol 1 mM 6571.6
Vitamin E 1 mM 7273.7
Proton leak OCR (%)
Coenzyme Q10 1 mM 2070.5
Tempol 1 mM 1970.8
Vitamin E 1 mM 1971.6
Maximal OCR (%)
Coenzyme Q10 1 mM 14377.1
Tempol 1 mM 14679.1
Vitamin E 1 mM 14976.2
Table 2
Bioenergetic proﬁles of mitochondrially targeted antioxidants. MES-13 cells were
seeded in a Seahorse XF-24 plate at 30,000 cells per well for 24 h. Cellular media
was replaced with low-buffered DMEM media prior to the assay and allowed to
equilibrate for 1 h at 37 1C. Basal OCR measurements were made for approxi-
mately 30 min followed by injection of MitoQ, MitoTempol, or MitoE. Two hours
later, the effects of oligomycin (1 mg/mL), FCCP (2 mM), and AA (10 mM) treatment
were determined. Basal OCR is calculated as the difference in OCR before
compound injection and after two hours of exposure. ATP linked is the difference
in OCR before and after Oligomycin. Proton Leak is the difference in OCR after
Oligomycin injection and Antimycin A. Maximal is the OCR after FCCP injection.
Data is expressed as a percent relative to the basal OCR rate before compound
injection. All data shown are mean7SEM, n¼3–5 group. npo0.05 vs. all groups,
statistical comparison performed using ANOVA and Newman–Keuls.
Bioenergetic proﬁles of mitochondrially targeted antioxidants
Basal OCR (%) Proton leak OCR (%)
MitoQ 0.01 mM 9472.2 MitoQ 0.01 mM 1475.3
0.1 mM 9771.3 0.1 mM 2572.1
1 mM 7074.1n 1 mM 4772.4n
MitoTempol 0.01 mM 10171.5 MitoTempol 0.01 mM 2171.4
0.1 mM 9172.8 0.1 mM 1970.7
1 mM 7073.0n 1 mM 4972.9n
MitoE 0.01 mM 10075.4 MitoE 0.01 mM 2371.5
0.1 mM 10371.6 0.1 mM 2273.1
1 mM 7371.2n 1 mM 3672.2n
ATP linked OCR (%) Maximal OCR (%)
MitoQ 0.01 mM 6671.7 MitoQ 0.01 mM 13675.8
0.1 mM 7273.3 0.1 mM 13073.3
1 mM 1373.2n 1 mM 6277.0n
MitoTempol 0.01 mM 6372.2 MitoTempol 0.01 mM 11976.2
0.1 mM 5772.7 0.1 mM 12474.5
1 mM 771.9n 1 mM 4276.8n
MitoE 0.01 mM 7272.9 MitoE 0.01 mM 17079.0
0.1 mM 7476.3 0.1 mM 15073.8
1 mM 2672.6n 1 mM 10871.3n
C. Reily et al. / Redox Biology 1 (2013) 86–93 91Finally, MitoE was tested and was found to cause a progressive
decrease in respiration following injection similar to TPMP
(Figs. 5C, 3A). Consistent with inhibition of oxidative phosphor-
ylation, MitoE caused an increase in glycolysis which was not
further stimulated by oligomycin or FCCP injection (Fig. 6C).
Further analysis of the effects of MitoQ, MitoTempol, and MitoE
compared to DTPP was also assessed and is shown in Fig. 7. In a
separate series of experiments, it was determined that non-
mitochondrially targeted compounds, Coenzyme Q10, Tempol,
and Vitamin E had no affect on mitochondrial respiration
(Table 1). However, the effects of the mitochondrially targeted
antioxidants at higher concentrations (1 mM) were signiﬁcantly
different than untreated controls (Table 2).Conclusion
Taken together, these data suggest that the alkyl TPPþ chain
elicits cellular bioenergetic responses which are consistent with
inhibition of oxidative phosphorylation and dependent on the
length of the alkyl chain. Previous studies have shown that the
effects of different carbon chain lengths which link the ubiquinol
moiety to the TPPþ group showed that retention and accumula-
tion of the compounds is dependent on the alkyl chain length
[17,21,31]. The hydrophobicity of the TPPþ compounds is an
important factor controlling accumulation of the compounds.
C. Reily et al. / Redox Biology 1 (2013) 86–9392For instance, TPMP (octan-1-ol/PBS partition coefﬁcient of 0.35)
slowly accumulates into mitochondria within cells before reach-
ing a steady state which is consistent with the slow onset of
inhibition of respiration shown in Fig. 4 [17]. However, a TPPþ
compound with a longer carbon chain linker such as DTPP or
MitoQ, (octan-1-ol/PBS partition coefﬁcient of 3000) accumulates
faster in mitochondria and reaches a steady state much more
rapidly and can then effectively uncouple the mitochondria
perhaps by cycling between the matrix and inter-membrane
space or possibly by interacting with proteins in the mitochon-
drial inner membrane to increase their catalysis of proton leak
across the mitochondrial inner membrane (Figs. 6 and 7) [17]. In
bovine aortic endothelial cell isolated mitochondria, MitoQ was
shown to induce superoxide, apoptosis, and redox cycling at
complex I in a concentration and time dependent manner [32].
Based on our ﬁndings, it is likely that the majority of these effects
can be ascribed to the non-speciﬁc effects of the TPPþ group on
cellular bioenergetics.
Importantly, the inhibition of oxidative phosphorylation achieved
in cell culture by TPPþ conjugated compounds under conditions
where metabolism and clearance of the drugs is minimal are
extremely unlikely to occur with oral dosing in either animal models
or human subjects. The effects of TPPþ compounds is also likely to be
dependent on the cell type since the bioenergetics of cells show a
wide range of responses depending on their number of mitochondria
and regulation [30]. In cell culture systems some of the bioenergetic
and redox effects ascribed to the effects of mitochondrially targeted
antioxidants are more likely due to the effects of the linker group and
are evident only at concentrations which are not achieved in
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